ADA and systemic lupus erythematosus: SLE patients with persistently positive ADA to rituximab had a significantly lower C3 at baseline when compared with ADA negative patients [mean 0.61 (0.23) g/l vs 0.87 (0.30) g/l, P = 0.026, Fig. 2B].